Related Experiment Video
Updated: Jan 30, 2026

Molecular Evolution of the Tre Recombinase
Published on: May 29, 2008
New evolutions in the BACE1 inhibitor field from 2014 to 2018
Chien-Chi Hsiao1, Frederik Rombouts1, Harrie J M Gijsen1
1Janssen Research & Development, Janssen Pharmaceutica N. V, Turnhoutseweg 30, B-2340 Beerse, Belgium.
Abstract:
β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD). Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors. This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018. Herein are summarized i) the structure-activity relationship, ii) the physiological results and iii) the potential risks from a lack of selectivity. This review also summarizes clinical scope, results and outlook of the compounds that have been or are currently under development in clinical trials.
More Related Videos
11:04Geomagnetic Field Gmf and Plant Evolution: Investigating the Effects of Gmf Reversal on Arabidopsis thaliana Development and Gene Expression
Published on: November 30, 2015
15:00Daily Transfers, Archiving Populations, and Measuring Fitness in the Long-Term Evolution Experiment with Escherichia coli
Published on: August 18, 2023
Related Concept Videos
The Evidence for Evolution
Convergent Evolution
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic Evolution
Contrary to the endosymbiont theory, the eukaryote-first hypothesis proposes that the simpler prokaryotic and...
Synteny and Evolution
Around 80 million years ago, the human and mice lineages diverged from the common ancestor. During the course of evolution, the ancestral...
Gene Evolution - Fast or Slow?